The small molecule simufilam dose‐dependently attenuates the worsening of seizures in a mouse model of tuberous sclerosis complex

Documenti analoghi

• Increased susceptibility to kainate‐induced seizures in a mouse model of tuberous sclerosis complex: Importance of sex and circadian cycle
  di: Mariana L. Pais, et al.
  Pubblicazione: (2024)
• Accumulated seizure burden predicts neurodevelopmental outcome at 36 months of age in patients with tuberous sclerosis complex
  di: S. Katie Z. Ihnen, et al.
  Pubblicazione: (2024)
• Lack of effectiveness and seizure worsening with cenobamate in pediatric patients with Dravet syndrome
  di: Rita Cagigal, et al.
  Pubblicazione: (2025)
• Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox–Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex
  di: Robert T. Wechsler, et al.
  Pubblicazione: (2024)
• Distinct peripheral pro‐inflammatory profile associated with tuberous sclerosis complex and epilepsy
  di: Renaud Balthazard, et al.
  Pubblicazione: (2025)